IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application

iOmx Therapeutics AG, a biopharmaceutical company based in Martinsried, Germany, has submitted a Clinical Trial Application (CTA) for IOMX-0675. This marks a critical step in their development of novel cancer treatments that leverage unexplored immune evasion biology. IOMX-0675 is a fully human antibody that targets LILRB1 and LILRB2, key immunosuppressive receptors found on immune cells. This approach aims to reprogram myeloid cells and restore the function of cytotoxic T cells, demonstrating significant anti-tumor potential in preclinical studies.

The CEO of iOmx, Apollon Papadimitriou, emphasized the unique and differentiated nature of IOMX-0675, highlighting its potential as a transformative treatment for cancer patients. The company's focus on innovative immune regulation strategies positions it at the forefront of developing new cancer therapies. Backed by international venture capital, iOmx continues to make advances with their growing pipeline of biomarker-enabled drug programs.